𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon-α2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation

✍ Scribed by Noboru Manabe; Michèle Chevallier; Philippe Chossegros; Xavier Causse; Sylviane Guerret; Christian Trépo; Jean-Alexis Grimaud

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
521 KB
Volume
18
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of α-interferon therapy on hepati
Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: A quantitative polymerase chain reaction study
✍ S. Brillanti; J. A. Garson; P. W. Tuke; C. Ring; M. Briggs; C. Masci; M. Migliol 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 505 KB

## Abstract Sera from 30 patients with community‐acquired, biopsy‐proven chronic non‐A, non‐B hepatitis (NANBH) were tested for antibodies to the C100 protein of hepatitis C virus (HCV). The 20 patients who showed reactivity in this assay were followed prospectively for 6 months, during which time

Hepatitis C viraemia rebound after “succ
Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non-A, non-B hepatitis
✍ Dr. J. A. Garson; S. Brillanti; C. Ring; P. Perini; M. Miglioli; L. Barbara 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 1 views

## Abstract A quantitative polymerase chain reaction (PCR) assay for hepatitis C viral RNA (HCV‐RNA) was used to monitor viraemia levels in six patients at multiple time points before, during, and after interferon therapy for chronic non‐A, non‐B hepatitis (NANBH). Prior to therapy, serum HCV‐RNA w

Low-dose interferon in chronic hepatitis
Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial
✍ Reichen, J. ;Solioz, M. ;B�hler, H. ;Gonvers, J.J. ;Knoblauch, M. ;Lavanchy, D. 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 635 KB

In this randomized, controlled multicenter trial we evaluated the effects of recombinant interferon-c~2b on galactose elimination capacity and histological activity index in 88 patients with chronic active hepatitis non-A/non-B. Forty-five patients were randomly assigned to treatment with interferon

Hepatitis B Viral Nucleotide Sequences i
Hepatitis B Viral Nucleotide Sequences in Non-A, Non-B or Hepatitis B Virus-Related Chronic Liver Disease
✍ Annalena Figus; Hubert E. Blum; Girish N. Vyas; Stefano De Virgilis; Antonio Cao 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 594 KB

The presence of serological markers of hepatitis B virus (HBV) infection and of hepatocellular HBV DNA were investigated in 19 HBsAg-negative patients with clinically and histologically significant chronic liver disease. Four cases negative for antibodies to HBsAg (anti-HBs), to the core antigen (an

Recombinant human α-interferon in patien
Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
✍ Patrick Marcellin; Nathalie Boyer; Emile Giostra; Claude Degott; Anne Marie Cour 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

We have conducted a multicenter randomized controlled trial comparing two doses of recombinant human a-interferon for efficacy in 60 patients with chronic non-A, non-B hepatitis. The source of infection appeared to be transfusion in 30 patients, intravenous drug abuse in 16 patients and was unknown